Latest News for: hcw

Edit

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed ...

Nasdaq Globe Newswire 13 Feb 2026
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune ... .
Edit

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune (Form 8-K) (HCW Biologics Inc)

Public Technologies 13 Feb 2026
HCW Biologics and WY Biotech ... HCW Biologics receiving cash fee and co-founder shares in Trimmune valued at $7.0 million ... HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory ... ("HCW Biologics") (NASDAQ.
Edit

Amendment to Initial Registration Statement (Form S-1/A) (HCW Biologics Inc)

Public Technologies 13 Feb 2026
HCW BIOLOGICS INC ... HCW Biologics Inc ... HCW Biologics Inc ... 10.1 Form of Indemnification Agreement between HCW Biologics Inc ... 10.5+ Employment Agreement, dated July 6, 2021, between Peter Rhode and HCW Biologics Inc ... Wong and HCW Biologics Inc.
Edit

Initial Registration Statement (Form S-1) (HCW Biologics Inc)

Public Technologies 11 Feb 2026
HCW BIOLOGICS INC ... HCW Biologics Inc ... HCW Biologics is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases.
Edit

Notice of Effectiveness (Form EFFECT) (HCW Biologics Inc)

Public Technologies 30 Jan 2026
) UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 ... HCW Biologics Inc ... HCW Biologics Inc.
Edit

Material Event (Form 8-K) (HCW Biologics Inc)

Public Technologies 31 Dec 2025
As previously disclosed, on August 19, 2025, HCW Biologics Inc. (the "Company" or "HCW Biologics") was notified by the Listing Qualifications Staff (the ... HCW Biologics Inc.
Edit

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules (Form 8-K) (HCW Biologics Inc)

Public Technologies 20 Nov 2025
). HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules. MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ ... Disclaimer. HCW Biologics Inc.
Edit

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

Nasdaq Globe Newswire 19 Nov 2025
MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ ... .
Edit

Material Agreement (Form 8-K) (HCW Biologics Inc)

Public Technologies 19 Nov 2025
) Item 1.01 Entry into a Material Definitive Agreement. On November 17, 2025, HCW Biologics Inc. (the "Company") and Beijing Trimmune Biotech Co., Ltd ... to Trimmune ... Attachments Original document Permalink. Disclaimer. HCW Biologics Inc ... (noodl.
Edit

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

Nasdaq Globe Newswire 18 Nov 2025
First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial ... .
Edit

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease (Form 8-K) (HCW Biologics Inc)

Public Technologies 18 Nov 2025
). HCW Biologics Announces. Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease ... MIRAMAR, Fla., November 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc ... Mary E ... About HCW Biologics.. HCW Biologics Inc ... HCW Biologics Inc.
Edit

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

Nasdaq Globe Newswire 14 Nov 2025
14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) ...
Edit

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results (Form 8-K) (HCW Biologics Inc)

Public Technologies 14 Nov 2025
HCW Biologics Reports Third Quarter 2025 ... Miramar, FL - November 14, 2025 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ ... About HCW Biologics. HCW Biologics Inc ... HCW Biologics Inc.
Edit

Quarterly Report for Quarter Ending September 30, 2025 (Form 10-Q) (HCW Biologics Inc)

Public Technologies 14 Nov 2025
Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the "Company," "HCW Biologics," "HCWB", "we," "us" and "our" refer to HCW Biologics Inc.
Edit

HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the ...

Nasdaq Globe Newswire 10 Nov 2025
HCW11-040 is a first-in-class pembrolizumab-based, tetra-valent immune ...

Article Search

tools
×
×
×
×